Erin Linnenbringer

Dr. Erin Linnenbringer

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
ELErin Linnenbringer
Erin Linnenbringer
AGArline T. Geronimus
Arline T. Geronimus
KDKia L. Davis
Kia L. Davis
JBJohn Bound
John Bound
LELibby Ellis
Libby Ellis
SGScarlett L. Gomez
Scarlett L. Gomez
Purpose: Studies of Black–White differences in breast cancer subtype often emphasize potential ancestry-associated genetic or lifestyle risk factors without fully considering how the social or economic implications of race in the U.S. may influence risk. We assess whether neighborhood racial composition and/or socioeconomic status are associated with odds of triple-negative breast cancer (TNBC) diagnosis relative to the less-aggressive hormone receptor-positive/HER2-negative subtype (HR+ /HER−), and whether the observed relationships vary across women’s race and age groups. Methods: We use multilevel generalized estimating equation models to evaluate odds of TNBC vs. HR+ /HER2− subtypes in a population-based cohort of 7291 Black and 74,208 White women diagnosed with breast cancer from 2006 to 2014. Final models include both neighborhood-level variables, adjusting for individual demographics and tumor characteristics. Results: Relative to the HR+ /HER− subtype, we found modestly lower odds of TNBC subtype among White women with higher neighborhood median household income (statistically significant within the 45–64 age group, OR = 0.981 per $10,000 increase). Among Black women, both higher neighborhood income and higher percentages of Black neighborhood residents were associated with lower odds of TNBC relative to HR+ /HER2−. The largest reduction was observed among Black women diagnosed at age ≥ 65 (OR = 0.938 per $10,000 increase; OR = 0.942 per 10% increase in Black residents). Conclusion: The relationships between neighborhood composition, neighborhood socioeconomic status, and odds of TNBC differ by race and age. Racially patterned social factors warrant further exploration in breast cancer subtype disparities research.

20 December 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FAFoluso O. Ademuyiwa
Foluso O. Ademuyiwa
PSPatricia Salyer
Patricia Salyer
YTYu Tao
Yu Tao
JLJingqin Luo
Jingqin Luo
WHWhitney L. Hensing
Whitney L. Hensing
LBLaura Bierut
Laura Bierut
PURPOSE: To determine if physicians' self-reported knowledge, attitudes, and practices regarding genetic counseling and testing (GCT) vary by patients' race. METHODS: We conducted a nationwide 49-item survey among breast oncology physicians in the United States. We queried respondents about their own demographics, clinical characteristics, knowledge, attitudes, practices, and perceived barriers in providing GCT to patients with breast cancer. RESULTS: Our survey included responses from 277 physicians (females, 58.8%; medical oncologists, 75.1%; academic physicians, 61.7%; and Whites, 67.1%). Only 1.8% indicated that they were more likely to refer a White patient than refer an African American patient for GCT, and 66.9% believed that African American women with breast cancer have lower rates of GCT than White women. Regarding perceived barriers to GCT, 63.4% of respondents indicated that African American women face more barriers than White women do and 21% felt that African American women require more information and guidance during the GCT decision-making process than White women. Although 32% of respondents indicated that lack of trust was a barrier to GCT in all patients, 58.1% felt that this was a greater barrier for African American women ( P < .0001). Only 13.9% believed that noncompliance with GCT is a barrier for all patients, whereas 30.6% believed that African American women are more likely than White women to be noncompliant ( P < .0001). CONCLUSION: We demonstrated that racial differences exist in oncology physicians' perceived barriers to GCT for patients with breast cancer. This nationwide survey will serve as a basis for understanding physicians' determinants of GCT for African American women and highlights the necessity of education and interventions to address bias among physicians. Awareness of such physician biases can enable further work to address inequities, ultimately leading to improved GCT equity for African American women with breast cancer.

21 January 2022 in Cancer Causes & Control
Verified
Journal Article
Open access
PDF file
GCGraham A Colditz
Graham A Colditz
DBDebbie L. Bennett
Debbie L. Bennett
JTJennifer Tappenden
Jennifer Tappenden
CBCourtney Beers
Courtney Beers
NANicole Ackermann
Nicole Ackermann
ATAdetunji Toriola
Adetunji Toriola
Purpose: The Joanne Knight Breast Health Cohort was established to link breast cancer risk factors, mammographic breast density, benign breast biopsies and associated tissue markers, and blood markers in a diverse population of women undergoing routine mammographic screening to study risk factors and validate models for breast cancer risk prediction.Methods: Women were recruited from November 2008 to April 2012 through the mammography service at the Joanne Knight Breast Health Center at Washington University in St. Louis, Missouri. Baseline questionnaire risk factors, blood, and screening mammograms were collected from 12,153 women. Of these, 1,672 were excluded for prior history of any cancer (except non-melanoma skin) or diagnosis of breast cancer within 6 months of blood draw/registration for the study, for a total of 10,481 women. Follow-up is through linking to electronic health records, tumor registry, and death register. Routine screening mammograms are collected every 1–2 years and incident benign breast biopsies and cancers are identified through record linkage to pathology and tumor registries. Formal fixed tissue samples are retrieved and stored for analysis. County-level measures of structural inequality were derived from publicly available resources.Results: Cohort Composition: median age at entry was 54.8 years and 26.7% are African American. Through 2020, 74% of participants have had a medical center visit within the past year and 80% within the past 2 years representing an average of 9.7 person-years of follow-up from date of blood draw per participant. 9,997 women are continuing in follow-up. Data collected at baseline include breast cancer risk factors, plasma and white blood cells, and mammograms prior to baseline, at baseline, and during follow-up.Conclusion: This cohort assembled and followed in a routine mammography screening and care setting that serves a diverse population of women in the St. Louis region now provides opportunities to integrate study of questionnaire measures, plasma and DNA markers, benign and malignant tissue markers, and repeated breast image features into prospective evaluation for breast cancer etiology and outcomes.

4 November 2025 in Genetics in Medicine
Verified
Journal Article
Closed access
ARAantaki Raisa
Aantaki Raisa
IMIrania Santaliz Moreno
Irania Santaliz Moreno
AAAmy Ayala
Amy Ayala
JHJada G. Hamilton
Jada G. Hamilton
JMJessica Mozersky
Jessica Mozersky
EWErika A. Waters
Erika A. Waters

1 April 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
AAAkila Anandarajah
Akila Anandarajah
HDHank Dart
Hank Dart
BMBailey Martin-Giacalone
Bailey Martin-Giacalone
MBMelinda Bachini
Melinda Bachini
BDBettina Drake
Bettina Drake
ELErin Linnenbringer
Erin Linnenbringer

SKSaira Khan
Saira Khan
BMBailey Martin-Giacalone
Bailey Martin-Giacalone
KWKayla Wallace
Kayla Wallace
BWBriana Wilson
Briana Wilson
CMChristine Marx
Christine Marx
BDBettina Drake
Bettina Drake
Few studies provide insights on how to incorporate community members’ perspectives of genomic research during the early phases of study development. Engaging with community members early and consistently throughout the research lifecycle could help identify and mitigate barriers to genomic research participation, particularly among groups with rare and understudied cancers. Methods: The Washington University Participant Engagement and Cancer Genome Sequencing (WU-PE-CGS) study formed a Participant Engagement Advisory Board (PEAB) consisting of patients, patient advocates, and patient advocacy organizations who represented the three understudied cancer populations: cholangiocarcinoma, early-onset colorectal cancer in Black Americans, and multiple myeloma in Black Americans. PEAB members were involved in PE-CGS from the time of the grant submission and provided input on key study procedures by participating in monthly project meetings and serving on the leadership team. PEAB recommendations are described in this process paper. Results: The PEAB provided key feedback on recruitment, consent, and survey development. Recruitment optimization focused on making the script more concise, tailoring to participant’s locale, and providing clearer participation expectations. Consent improvements prioritized key information, addressed data protection, and clarified the process of returning genetic results. Survey enhancements included refining scientific terminology and ensuring inclusivity across the cancer continuum. Conclusions: The PEAB provided valuable feedback that improved the development and implementation of WU-PE-CGS research processes. Incorporating the PEAB’s suggestions helped ensure that patients with rare and understudied cancers were successfully enrolled into the WU-PE-CGS. The PEAB will continue to contribute throughout all study phases.